XGN | Day Chart | June Q2 26'Exagen, Inc.BATS:XGNStudyGuideTAMARKET-BEATING SCORE = 7/10 XGN PEGY -0.18 — undervalued vs. growth rate. Strong candidate to beat the market. XGN EPS growth 19.65% — solid, in line with market leaders. XGN revenue growing 19.65% YoY — strong top-line supports market-beating returns. XGN gross margin 58.32% — strong moat, characteristic of long-run market beaters. XGN FCF $-14.13M negative — cash burn is a risk factor against market-beating returns. XGN D/E ratio 0.94 — conservative leverage, balance sheet resilience favors outperformance. --------------------------------- "Exagen is a strong competitor in the medical technology industry, offering diagnostic testing products for rheumatic and autoimmune diseases with a primary focus on SLE and RA." ---------------------------------- ** T.A explained ** Multiple Time-Frame Analysis; Color Code | Strength favors the higher timeframe. Yearly timeframe = black Monthly timeframe = pink weekly = grey daily = red 4hr = orange 1hr = yellow 15min = blue 5min = green if they are shown. (Level visibility on intervals is set to timeframe the level was found on and below to keep chart view organized.)